Rick Klausner is the founder of Lyell Immunopharma. Lyell Immunopharma has raised $493M in total funding. Latest round: IPO. Based in Seattle, United States.
Rick Klausner serves as the Chair of the Board of Directors at Lyell Immunopharma, a T cell reprogramming company dedicated to mastering T cells to cure patients with solid tumors. He is actively involved in providing scientific guidance to the company's scientists and leadership team. Lyell Immunopharma focuses on addressing T cell exhaustion and lack of durable stemness to develop new medicines using its proprietary Gen-R and Epi-R technology platforms.
Full founder directory · Investor directory · Company funding database · Fundraising library